Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Calcium channel blockers. Is it time to split the lump?

¹Department of Veterans Affairs Medical Center, Miami, FL 33125-1693, USA.

American Journal of Hypertension

|March 1, 1995

Summary

The term "calcium channel blocker" inaccurately groups dissimilar drugs. Phenylalkylamines and benzothiazepines are distinct from dihydropyridines, necessitating revised nomenclature for clarity in cardiovascular pharmacology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Blood pressure elevation drives microalbuminuria.

Journal of human hypertension·2010

Same author

Captopril is an unlikely cause of nephrotic syndrome.

Archives of internal medicine·2001

Same author

Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial.

Hypertension (Dallas, Tex. : 1979)·2001

Same author

Combination therapy as the initial drug treatment for hypertension: when is it appropriate?

American journal of hypertension·2001

Same author

Ventricular and myocardial function following treatment of hypertension.

The American journal of cardiology·2001

Same author

Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: observations from a Department of Veterans Affairs Cooperative Study.

Archives of internal medicine·2000

Area of Science:

Pharmacology
Cardiovascular Medicine
Drug Classification

Background:

Current antihypertensive drug classifications are generally consistent, except for the broad category of "calcium channel blockers."
This umbrella term encompasses drugs with markedly different pharmacological profiles and clinical applications.
Existing classifications fail to distinguish between drugs with similar and dissimilar mechanisms and effects.

Purpose of the Study:

To propose a revised classification system for calcium-related cardiovascular drugs.
To differentiate between phenylalkylamines/benzothiazepines and dihydropyridines based on their distinct pharmacologic properties.
To enhance clarity and precision in the terminology used for antihypertensive agents.

Main Methods:

Comparative analysis of the pharmacological properties of different calcium channel-acting drug classes.
Review of existing drug classification systems in cardiovascular medicine.
Proposal of new terminology based on receptor binding and clinical effects.

Main Results:

Phenylalkylamines (e.g., verapamil) and benzothiazepines (e.g., diltiazem) share similar clinical pharmacology, including negative chronotropic effects.
Dihydropyridines (e.g., nifedipine) exhibit distinct properties, such as potential for tachycardia and peripheral edema, differing from verapamil and diltiazem.
The alpha 1 component of the calcium channel has distinct binding sites for these drug subclasses.

Conclusions:

The current "calcium channel blocker" classification is pharmacologically imprecise.
Proposed terminology: "calcium antagonists" for the broad class, "calcium channel blockers" for verapamil/diltiazem types, and "dihydropyridines" (DHPs) for nifedipine types.
Revised nomenclature will improve understanding and communication in cardiovascular drug therapy.

Related Experiment Videos